Ana Oaknin - Concepedia

Author

Ana Oaknin

Vall d'Hebron Hospital Universitari ORCID

Also Known As

A Oaknin, A. M. Oaknin, A. Oaknin, A.n.a. Oaknin, Ana Oaknin, Anna Oaknin, Antonio Gonzalez Martin, Constanza Maximiano, Cristina Saura, N. Normanno

710

Publications

34.9K

Citations

H-Index

Concepts

All Affiliations

Vall d'Hebron Hospital Universitari Vall d'Hebron Institute of Oncology Memorial Sloan Kettering Cancer Center European Institute of Oncology Princess Margaret Cancer Centre

About

Ana Oaknin is an author at Vall d'Hebron Hospital Universitari specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	93	13.5K
2	Health Sciences	15	18	1.8K
3	Public Health	10	11	357
4	Immunology	10	11	528
5	Cell Biology	3	3	93

Ana Oaknin

185

Publications

27.5K

Citations

H-Index

Page 1

	Year	Citations
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, New England Journal of Medicine	2018	2.7K
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial M. William Audeh, James Carmichael, Richard T. Penson, The Lancet MedicineCancer ManagementGynecologyRecurrent Ovarian CancerPolymerase Inhibitor Olaparib	2010	2.3K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial Éric Pujade-Lauraine, Felix Hilpert, B. Weber, Journal of Clinical Oncology	2014	1.6K
Improved Survival with Bevacizumab in Advanced Cervical Cancer Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, New England Journal of Medicine	2014	1.5K
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, The Lancet Oncology MedicinePharmacologyPathologyCancer TreatmentOncology	2016	1.2K
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer Robert L. Coleman, Gini F. Fleming, Mark F. Brady, New England Journal of Medicine	2019	886
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin, Annals of Oncology Antitumor ActivityOncologyMedicineGynecologyImmune Checkpoint Inhibitor	2019	786
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Journal of Clinical Oncology	2023	767
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, The Lancet Advanced Cervical CancerCervical Cancer ManagementCervical CancerCervical HealthMedicine	2017	656

Page 1